{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:58:09Z","timestamp":1776812289439,"version":"3.51.2"},"reference-count":26,"publisher":"Georg Thieme Verlag KG","issue":"02","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The objective of this systematic study was to assess the perioperative management and outcome of surgery in pediatric patients with hemophilia A\/B and inhibitors compared to nonhemophilic pediatric patients.<\/jats:p>\n                  <jats:p>The surgical outcome of 69 port catheter operations in patients with hemophilia who developed inhibitory antibodies against the administered factor was compared to 51 procedures in the control group. In the patients with hemophilia and inhibitors, a standardized protocol for recombinant activated factor VII was used to prevent perioperative bleeding.<\/jats:p>\n                  <jats:p>Hemophilic pediatric patients with inhibitors showed no significant differences in perioperative management (blood transfusion: p\u2009=\u20090.067, duration of surgery: p\u2009=\u20090.69; p\u2009=\u20090.824) in comparison to patients without hemophilia. The length of hospital stay was significantly longer in pediatric patients with hemophilia and inhibitors (20 days vs. 4 days for insertion; 12 days vs. 1 day for explantation). Moreover, no statistically significant difference was found for secondary bleeding (three patients with hemophilia vs. none in the control group; p\u2009=\u20090.11) or surgical complications (five hemophilia patients vs. none with grade I complication; one hemophilia patient vs. none with grade II complications; p\u2009=\u20090.067).<\/jats:p>\n                  <jats:p>This study has demonstrated that port catheter insertion and removal is safe in these patients. Moreover, it shows the importance of a coordinated approach with a multidisciplinary team.<\/jats:p>","DOI":"10.1055\/a-2337-3687","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T19:25:48Z","timestamp":1726169148000},"page":"136-140","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative Management for Port Catheter Procedures in Pediatric Patients with Severe Hemophilia and Inhibitors"],"prefix":"10.1055","volume":"46","author":[{"given":"Anna","family":"Woestemeier","sequence":"additional","affiliation":[{"name":"Department for General, Visceral, Thoracic and Vascular Surgery, University Hospital of Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Horneff","sequence":"additional","affiliation":[{"name":"Institute of Experimental Haematology and Transfusions Medicine, University Hospital of Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent Marlon","family":"L\u00fcder","sequence":"additional","affiliation":[{"name":"Department for General, Visceral, Thoracic and Vascular Surgery, University Hospital of Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Nadal","sequence":"additional","affiliation":[{"name":"Institute for Medical Biometrics, Informatics and Epidemiology, University Hospital of Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Koscielny","sequence":"additional","affiliation":[{"name":"Department for General and Visceral Surgery, St. Elisabeth-Hospital Leipzig, Leipzig, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg C.","family":"Kalff","sequence":"additional","affiliation":[{"name":"Department for General, Visceral, Thoracic and Vascular Surgery, University Hospital of Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Institute of Experimental Haematology and Transfusions Medicine, University Hospital of Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Goldmann","sequence":"additional","affiliation":[{"name":"Institute of Experimental Haematology and Transfusions Medicine, University Hospital of Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Lingohr","sequence":"additional","affiliation":[{"name":"Department for General, Visceral, Thoracic and Vascular Surgery, University Hospital of Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1365-2141.2010.08139.x","article-title":"A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A","volume":"149","author":"M Richards","year":"2010","journal-title":"Br J Haematol"},{"issue":"12","key":"ref2","first-page":"1571","article-title":"French guidelines. Long-term prophylaxis for severe haemophilia A and B children to prevent haemophiliac arthropathy [in French]","volume":"16","author":"S Meunier","year":"2009","journal-title":"Arch Pediatr"},{"issue":"13","key":"ref3","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"J Oldenburg","year":"2015","journal-title":"Blood"},{"issue":"S 04","key":"ref4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2516.2004.01009.x","article-title":"Inhibitors in haemophilia: pathophysiology","volume":"10","author":"J M Saint-Remy","year":"2004","journal-title":"Haemophilia"},{"issue":"S 77","key":"ref5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/ejh.12499","article-title":"Strategies for inhibitor treatment and costs in the short and long term: a critical evaluation of recent clinical studies","volume":"94","author":"M R Baghaipour","year":"2015","journal-title":"Eur J Haematol"},{"issue":"07","key":"ref6","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1055\/s-0033-1356574","article-title":"Challenges in the management of hemophilia B with inhibitor","volume":"39","author":"A Batorova","year":"2013","journal-title":"Semin Thromb Hemost"},{"issue":"09","key":"ref7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"S W Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2516.2004.00943.x","article-title":"Consensus recommendations for use of central venous access devices in haemophilia","volume":"10","author":"B M Ewenstein","year":"2004","journal-title":"Haemophilia"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/17434440.2.6.699","article-title":"Central venous access devices in patients with hemophilia","volume":"2","author":"L A Valentino","year":"2005","journal-title":"Expert Rev Med Devices"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.amjsurg.2009.02.018","article-title":"Perioperative management and outcome of general and abdominal surgery in hemophiliacs","volume":"199","author":"G Goldmann","year":"2010","journal-title":"Am J Surg"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00423-014-1185-7","article-title":"Value and risk of laparoscopic surgery in hemophiliacs-experiences from a tertiary referral center for hemorrhagic diatheses","volume":"399","author":"P Lingohr","year":"2014","journal-title":"Langenbecks Arch Surg"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00345-012-0988-9","article-title":"Urological surgery in patients with hemorrhagic bleeding disorders Hemophilia A, Hemophilia B, von Willebrand disease: a retrospective study with matched pairs analysis","volume":"31","author":"S Rogenhofer","year":"2013","journal-title":"World J Urol"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1182\/blood.V84.7.2197.2197","article-title":"Analysis of intron 22 inversions of the factor VIII gene in severe hemophilia A: implications for genetic counseling","volume":"84","author":"P V Jenkins","year":"1994","journal-title":"Blood"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"D Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1053\/j.seminhematol.2005.11.024","article-title":"Surgery in hemophilia. The general view: patient selection, timing, and preoperative assessment","volume":"43","author":"J Ingerslev","year":"2006","journal-title":"Semin Hematol"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/1076029616658116","article-title":"Outcomes in patients with hemophilia and von Willebrand disease undergoing invasive or surgical procedures","volume":"23","author":"J Chapin","year":"2017","journal-title":"Clin Appl Thromb Hemost"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2141.2012.09089.x","article-title":"How to manage invasive procedures in children with haemophilia","volume":"157","author":"R C Ljung","year":"2012","journal-title":"Br J Haematol"},{"issue":"S 02","key":"ref19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2516.2004.00938.x","article-title":"Surgery in haemophilic patients with inhibitor: 20 years of experience","volume":"10","author":"M Quintana-Molina","year":"2004","journal-title":"Haemophilia"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1046\/j.0007-1048.2001.03324.x","article-title":"Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors","volume":"116","author":"N O'Connell","year":"2002","journal-title":"Br J Haematol"},{"issue":"S 02","key":"ref21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2516.2004.00940.x","article-title":"Cases of surgery in high-responder haemophilia patients","volume":"10","author":"J Goudemand","year":"2004","journal-title":"Haemophilia"},{"issue":"12","key":"ref22","first-page":"CD004449","article-title":"Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors","volume":"2015","author":"D Matino","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"S 01","key":"ref23","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/00001721-200004001-00006","article-title":"Management and monitoring of recombinant activated factor VII","volume":"11","author":"J Ingerslev","year":"2000","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"05","key":"ref24","first-page":"773","article-title":"Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery","volume":"80","author":"A D Shapiro","year":"1998","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1055\/s-0043-1777766","article-title":"Surgical experience from the STASEY study of emicizumab prophylaxis in people with hemophilia A with factor VIII inhibitors","volume":"8","author":"G Castaman","year":"2024","journal-title":"TH Open"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/hae.14322","article-title":"Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery","volume":"27","author":"V Jim\u00e9nez-Yuste","year":"2021","journal-title":"Haemophilia"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2337-3687.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:30:44Z","timestamp":1776810644000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2337-3687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":26,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2026,4,21]]},"published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2337-3687","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}